EcoDrugPlus

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCLMG00005009376
Gene Symbol: CCR9
1 Cross references
194 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSCLMG00005018050
Gene Symbol: CXCR2
1 Cross references
275 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCLMG00005005995
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSCLMG00005019760
Gene Symbol: DNMT1
1 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCLMG00005011678
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCLMG00005007456
Gene Symbol: TOP2A
1 Cross references
168 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCLMG00005005013
Gene Symbol: TOP2A
1 Cross references
168 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCLMG00005009292
Gene Symbol: TOP2B
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSCLMG00005013136
Gene Symbol: TOP1A
1 Cross references
208 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCLMG00005009119
Gene Symbol: EPHA3
1 Cross references
211 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCLMG00005006074
Gene Symbol: F2RL3
1 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSCLMG00005017685
Gene Symbol: FAUA
1 Cross references
299 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).